Recent advances in gene editing technologies, such as CRISPR, have opened new possibilities for improving ACT. These technologies allow for more precise modifications of T cells, potentially enhancing their efficacy and safety. Researchers are also exploring combination therapies that use ACT alongside other treatments like checkpoint inhibitors to overcome resistance mechanisms and improve outcomes.
